SSGJ-626
/ 3SBio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
July 08, 2026
Evaluation of 626 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=50 | Completed | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting ➔ Completed
Trial completion
November 27, 2025
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
(clinicaltrials.gov)
- P1/2 | N=198 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
September 23, 2025
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
(clinicaltrials.gov)
- P1/2 | N=198 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P1/2 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
1 to 3
Of
3
Go to page
1